Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine and Tolvaptan for Severe Hyponatremia in Cirrhosis
NCT05060523Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in hyponatremia comparing Tolvaptan + Midodrine with Tolvaptan + Placebo (2 arms). Primary endpoint: Improvement in Na+ to 125meq/L at 1 week. Status: unknown.
02
Drugs
midodrine
03
Conditions
hyponatremia
Beyond the preview
Go deeper on NCT05060523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060523.